These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37767674)

  • 41. Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial.
    Pabon M; Claggett BL; Wang X; Miao ZM; Chatur S; Bhatt AS; Vaduganathan M; Fang JC; Desai AS; Jhund P; Martinez F; de Boer RA; Kosiborod MN; Lam CSP; Shah SJ; Hernandez AF; McMurray JJV; Solomon SD; Vardeny O
    Eur J Heart Fail; 2023 Sep; 25(9):1663-1670. PubMed ID: 37632711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
    Dewan P; Solomon SD; Jhund PS; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; DeMets DL; Sabatine MS; Bengtsson O; Sjöstrand M; Langkilde AM; Anand IS; Bělohlávek J; Chopra VK; Dukát A; Kitakaze M; Merkely B; O'Meara E; Schou M; Vinh PN; McMurray JJV;
    Eur J Heart Fail; 2020 Jul; 22(7):1247-1258. PubMed ID: 32539224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
    Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L
    JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial.
    Wang X; Lam CSP; Vaduganathan M; Kondo T; Yang M; Han Y; Pham VN; Chiang CE; Kitakaze M; Miao ZM; Jhund PS; Desai AS; Inzucchi SE; de Boer RA; Martinez FA; Kosiborod MN; Hernandez AF; Claggett B; Langkilde AM; McMurray JJV; Solomon SD
    JACC Asia; 2024 Feb; 4(2):108-118. PubMed ID: 38371292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
    Solomon SD; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Lindholm D; Wilderäng U; Öhrn F; Claggett B; Langkilde AM; Petersson M; McMurray JJV
    Eur J Heart Fail; 2021 Jul; 23(7):1217-1225. PubMed ID: 34051124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER.
    Desai AS; Jhund PS; Claggett BL; Vaduganathan M; Miao ZM; Kondo T; Barkoudah E; Brahimi A; Connolly E; Finn P; Lang NN; Mc Causland FR; McGrath M; Petrie MC; McMurray JJV; Solomon SD
    JAMA Cardiol; 2022 Dec; 7(12):1227-1234. PubMed ID: 36189985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.
    Farmakis D; Simitsis P; Bistola V; Triposkiadis F; Ikonomidis I; Katsanos S; Bakosis G; Hatziagelaki E; Lekakis J; Mebazaa A; Parissis J
    Clin Res Cardiol; 2017 May; 106(5):359-368. PubMed ID: 27999929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2023 Nov; 57(11):1291-1301. PubMed ID: 36800904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
    Yang M; Kondo T; Talebi A; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
    Eur J Heart Fail; 2024 Jul; 26(7):1524-1538. PubMed ID: 38700986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
    J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial.
    Solomon SD; Ostrominski JW; Vaduganathan M; Claggett B; Jhund PS; Desai AS; Lam CSP; Pitt B; Senni M; Shah SJ; Voors AA; Zannad F; Abidin IZ; Alcocer-Gamba MA; Atherton JJ; Bauersachs J; Ma CS; Chiang CE; Chioncel O; Chopra V; Comin-Colet J; Filippatos G; Fonseca C; Gajos G; Goland S; Goncalvesová E; Kang SM; Katova T; Kosiborod MN; Latkovskis G; Lee AP; Linssen GCM; Llamas-Esperón G; Mareev V; Martinez FA; Melenovský V; Merkely B; Nodari S; Petrie MC; Saldarriaga CI; Saraiva JFK; Sato N; Schou M; Sharma K; Troughton R; Udell JA; Ukkonen H; Vardeny O; Verma S; von Lewinski D; Voronkov LG; Yilmaz MB; Zieroth S; Lay-Flurrie J; van Gameren I; Amarante F; Viswanathan P; McMurray JJV
    Eur J Heart Fail; 2024 Jun; 26(6):1334-1346. PubMed ID: 38733212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial.
    Peikert A; Chandra A; Kosiborod MN; Claggett BL; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Janssens SP; Belohlávek J; Borleffs CJW; Dobreanu D; Langkilde AM; Bengtsson O; Petersson M; McMurray JJV; Solomon SD; Vaduganathan M
    JAMA Cardiol; 2023 Jul; 8(7):684-690. PubMed ID: 37208998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Starr JA; Pinner NA
    Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction.
    Straw S; Cole CA; McGinlay M; Drozd M; Slater TA; Lowry JE; Paton MF; Levelt E; Cubbon RM; Kearney MT; Witte KK; Gierula J
    Clin Res Cardiol; 2023 Jan; 112(1):111-122. PubMed ID: 35781605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.
    Chatur S; Vaduganathan M; Claggett BL; Mc Causland FR; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Sabatine MS; Kober L; Ponikowski P; Merkely B; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2023 Nov; 82(19):1854-1863. PubMed ID: 37634707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cryoballoon ablation for atrial fibrillation in patients with heart failure with mildly reduced and preserved ejection fraction.
    Chen C; Cheng K; Gao X; Zou T; Pang Y; Ling Y; Xu Y; Xu Y; Chen Q; Zhu W; Ge J
    ESC Heart Fail; 2023 Feb; 10(1):518-531. PubMed ID: 36325978
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF Trial.
    Selvaraj S; Patel S; Sauer AJ; McGarrah RW; Jones P; Kwee LC; Windsor SL; Ilkayeva O; Muehlbauer MJ; Newgard CB; Borlaug BA; Kitzman DW; Shah SJ; Shah SH; Kosiborod MN;
    JACC Heart Fail; 2024 Jun; 12(6):999-1011. PubMed ID: 38639697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
    Bhatt AS; Kosiborod MN; Vaduganathan M; Claggett BL; Miao ZM; Kulac IJ; Lam CSP; Hernandez AF; Martinez F; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2023 Jul; 25(7):981-988. PubMed ID: 37211977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
    Savarese G; Uijl A; Lund LH; Anker SD; Asselbergs F; Fitchett D; Inzucchi SE; Koudstaal S; Ofstad AP; Schrage B; Vedin O; Wanner C; Zannad F; Zwiener I; Butler J
    J Card Fail; 2021 Aug; 27(8):888-895. PubMed ID: 34364665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.